**Name of journal:** *World Journal of Diabetes*

**ESPS Manuscript NO: 7191**

**Columns: REVIEW**

**Origin and therapy for hypertriglyceridaemia in type 2 diabetes**

Pang J *et al*. Origin and therapy for hypertriglyceridaemia in type 2 diabetes

Jing Pang, Dick C Chan, Gerald F Watts

**Jing Pang, Dick C Chan, Gerald F Watts,** School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6847, Australia

**Gerald F Watts,** Lipid Disorders Clinic, Royal Perth Hospital, Perth, WA 6847, Australia

**Author contributions:** All the authors contributed to this paper.

**Correspondence to: Gerald F Watts, DSc, PhD, MD, FRACP, FRCP,** School of Medicine and Pharmacology, University of Western Australia, GPO Box X2213, Perth, WA 6847 Australia. [gerald.watts@uwa.edu.au](mailto:gerald.watts@uwa.edu.au)

**Telephone:** +6-8-92240245 **Fax:** +6-8-92240245

**Received:** November 5, 2013 **Revised:** March 8, 2014

**Accepted:** March 17, 2014

**Published online:**

**Abstract**

Hypertriglyceridaemia (HTG) is a risk factor for cardiovascular disease (CVD) in type 2 diabetes and is caused by the interaction of genes and non-genetic factors, specifically poor glycaemic control and obesity. In spite of statin treatment, residual risk of CVD remains high in type 2 diabetes, and this may relate to HTG and atherogenic dyslipidaemia. Treatment of HTG emphasises correcting secondary factors and adverse lifestyles, in particular, diet and exercise. Pharmacotherapy is also required in most type 2 diabetic patients. Statins are the first-line therapy to achieve recommended therapeutic targets of plasma low-density liporpteoin cholesterol and non-high-density lipoprotein cholesterol. Fibrates, ezetimibe and n-3 fatty acids are adjunctive treatment options for residual and persistent hypertriglyceridaemia. Evidence for the use of niacin has been challenged by non-significant CVD outcomes in two recent large clinical trials. Further investigation is required to clarify the use of incretin-based therapies for HTG in type 2 diabetes. Extreme HTG, with risk of pancreatitis, may require insulin infusion therapy or apheresis. New therapies targeting hypertriglyceridaemia in diabetes need to be tested in clinical endpoint trials. The purpose of this review is to examine the current evidence and provide practical guidance on the management of HTG in type 2 diabetes.

©2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Diabetes; Triglyceride; Therapy

**Core tip:** Diabetic dyslipidaemia relates collectively to hyperglycaemia, insulin resistance, hyperinsulinaemia, abdominal visceral adipose disposition, increased liver fat content, and dysregulated fatty acid metabolism. Insulin resistance in diabetes induces hypertriglyceridaemia by increasing the enterocytic production of chylomicrons and an impaired clearance capacity is also involved. Usual care for diabetic dyslipidemia is statin treatment, but a significant proportion of patients have residual dyslipidemia, related to hypertriglyceridaemia and atherogenic dyslipidaemia. Current evidence supports the use of fenofibrate in type 2 diabetics with high triglyceride levels.

Pang J, Chan DC, Watts GF. Origin and therapy for hypertriglyceridaemia in type 2 diabetes

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Hypertriglyceridaemia (HTG) is an important risk factor for cardiovascular disease (CVD)[[1](#_ENREF_1)] and is defined as a fasting plasma triglyceride concentration > 95th percentile for age and sex in a population. HTG may be as prevalent as 50% in type 2 diabetes and is often unresponsive to statin treatment[[2](#_ENREF_2),[3](#_ENREF_3)]. We review recent evidence on the role of HTG in atherosclerotic CVD and provide practical guidance on the management of HTG in type 2 diabetes.

**PATHOPHYSIOLOGY OF HYPERTRIGLYCERIDAEMIA IN TYPE 2 DIABETES**

Triglycerides, which originate from the intestine postprandially or endogenously from the liver, are packaged into lipoprotein particles containing apolipoprotein B-48 (apoB-48; chylomicrons) and apolipoprotein B-100 (apoB-100; VLDL), respectively. Abnormalities in triglyceride-rich lipoprotein (TRL) metabolism are cardinal features of type 2 diabetes. Metabolic dysregulation resulting in HTG include enhanced hepatic secretion of TRL due to insulin resistance and delayed clearance of TRL involving lipoprotein lipase (LPL)-mediated lipolysis. Several genes causing loss of function of LPL can result in severe HTG, such as LPL, APOC2, APOA5, GPD1, CPIHBP1 and LMF1[[4](#_ENREF_4),[5](#_ENREF_5)]. Very few patients will have a monogenic disorder. Individuals with severe HTG are likely to be homozygous or compound heterozygous for mutations which impair the TRL catabolic pathway. However, HTG in type 2 diabetes due to several genes with mild effects that interact with non-genetic factors is probably more likely. These non-genetic factors include hyperglycaemia, alcohol abuse, concomitant medication, sedentary lifestyle, chronic kidney disease and insulin resistance[[6](#_ENREF_6)]

Insulin resistance activates de novo lipogenesis, resulting in oversecretion of hepatic TRLs. This is also evident in the postprandial state, with enterocytic oversecretion of TRLs in the form of chylomicrons. With both secretion pathways on overdrive, competition between the TRLs and their remnants for lipolytic and receptor-mediated clearance further induces HTG. Insulin resistance is also associated with increased rates of apolipoprotein C-III (apoC-III) secretion, which further impairs receptor-mediated uptake of hepatic chylomicron remnants[[7](#_ENREF_7)]. Glucose has also found to activate apoC-III transcription, which may be the link between hyperglycaemia, HTG and CVD in type 2 diabetics[[8](#_ENREF_8)].

Both LPL and hepatic lipase (HL) control the clearance of triglycerides. HL plays a particularly important role in the delipidation cascade from VLDL to LDL. Triglyceride-rich VLDL derives small, dense LDL particles which are more susceptible to oxidation[[9](#_ENREF_9)]. Additionally, increased TRL in postprandial diabetic dyslipidaemia leads to the exchange of TRL-triglyceride for HDL- cholesteryl ester and hence, triglyceride enrichment of HDL via CETP. CETP progressively decreases postprandially and limits the efficient removal of cholesterol[[10](#_ENREF_10)]. Triglycerides in HDL are good substrates for hepatic lipase which leads to the production of small dense HDL particles and enhanced apolipoprotein A-I (apoA-I) clearance[[11](#_ENREF_11)].

Given that HTG is related to a plethora of risk factors, the lack of independent association between triglyceride and CVD is expected[[12](#_ENREF_12)], although two recent Mendelian randomisation studies have shown a causal association between variations in two related genes (LPL and APOA5) and myocardial infarction[[13](#_ENREF_13)]. This supports that TRL causes CVD, and this probably applies to diabetes.

Hence, diabetic dyslipidaemia relates collectively to hyperglycaemia, insulin resistance, hyperinsulinaemia, abdominal visceral adipose disposition, increased liver fat content, and dysregulated fatty acid metabolism. Diabetic dyslipidaemia may also be exacerbated by chronic kidney disease and by co-prescribed medications, such as thiazide diuretics, non-selective beta-blockers and steroids.

**MANAGEMENT OF HYPERTRIGLYCERIDAEMIA IN TYPE 2 DIABETES**

***Measurement and assessment***

Triglyceride concentration is commonly measured with a fasting lipid profile. The fasting triglyceride level facilitates the calculation of the LDL cholesterol by the Friedewald equation[[14](#_ENREF_14)]. Non-fasting triglyceride concentrations are reflective of the postprandial state and can be useful as a simple and practical screening test for HTG. A second non-fasting measurement is recommended if the initial triglyceride is > 2.0 mmol/L. Two or more measurements of elevated triglyceride in both postabsorptive and postprandial states are clinically indicative of HTG. Categories of HTG are differentially defined in international guidelines (Table 1).

Non-HDL cholesterol is another appealing method of assessment as it does not attract additional costs. Non-HDL cholesterol (total cholesterol minus HDL-cholesterol) does not rely on a fasting triglyceride concentration and provides a simple amalgamated measure all the atherogenic lipoproteins[[15](#_ENREF_15)]. ApoB, on the other hand, does not adequately reflect chylomicron remnants and involves additional laboratory expenses. Discordance between non-HDL cholesterol and apoB measures, particularly in patients with type 2 diabetes and HTG, questions its value in assessing risk and defining treatment targets[[16](#_ENREF_16)]. In the context of statin-treated patients, a meta-analysis has shown that non-HDL cholesterol is superior in its association with risk of future major cardiovascular events compared with LDL cholesterol and apoB[[17](#_ENREF_17)]. Other TRL markers such as remnant-like particle cholesterol, apoC-III and apoB-48 are expensive and are yet to be clinically established.

The hypertriglyceridaemic waist (HTWC) phenotype has suggested to be useful in assessing glucometabolic risk[[18-21](#_ENREF_18)], in particular, among patients with a family history of diabetes[[22](#_ENREF_22)]. The HTWC phenotype is defined by a waist circumference of ≥ 90 cm in men and ≥ 85 cm in women and triglyceride concentration ≥ 2.0 mmol/L. Men with the HTWC phenotype have been shown to have a four-fold risk of diabetes compared to those with waist circumference and triglyceride in the normal ranges[[23](#_ENREF_23)]. There is also a two-fold risk for development of coronary artery disease (CAD) in women[[24](#_ENREF_24)] and an overall deterioration of cardiometabolic risk[[25](#_ENREF_25)] in relation to progression of type 2 diabetes[[26](#_ENREF_26)].

***Guidelines and recommendations***

Guidelines for managing HTG in diabetes have been published, with lifestyle modifications being first-line therapy followed by statins, fibrates, n-3 fatty acids and/or niacin[[27-30](#_ENREF_27)]. The National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines recommend LDL cholesterol as the primary treatment target and non-HDL cholesterol as a secondary target, with the exception of a fasting triglyceride > 5.60 mmol/L, only then, triglyceride becomes the primary target owing to the risk of pancreatitis[[31](#_ENREF_31)]. A simplification of the NCEP ATP III guideline is presented in Table 2. Regardless of atherosclerotic disease and presence of other cardiovascular risk factors, type 2 diabetes is considered a coronary heart disease risk equivalent by the NCEP ATP III.

The American Diabetes Association (ADA)/American College of Cardiology Foundation consensus statement recommends a non-HDL cholesterol target of 3.40 mmol/L in diabetic patients with no other cardiovascular risk factor and a target of 2.60 mmol/L if there is one or more cardiovascular risk factor such as hypertension, smoking, dyslipidaemia and family history of CAD[[32](#_ENREF_32)]. The LDL cholesterol target is 2.60 and 1.80 mmol/L, respectively[[32](#_ENREF_32)] or alternatively a 30%-40% reduction from baseline levels[[30](#_ENREF_30)]. The ADA position statement is the only guideline that provides desirable targets for triglyceride levels for patients with type 2 diabetes: less than 1.70 mmol/L [[30](#_ENREF_30)]. Both the NCEP ATP and ADA guidelines place emphasis on weight loss and physical activity. A summary of recommended treatment targets is presented in Table 3.

The Scientific Statement from the American Heart Association (AHA) on triglycerides and CVD particularly emphasises the dietary and lifestyle modifications (weight loss, macronutrient distribution and aerobic exercise) for the treatment of elevated triglycerides, presenting a practical algorithm for screening and management[[28](#_ENREF_28)]. The European Society of Cardiology (ESC) guidelines on diabetes and CVD developed in collaboration with the European Association for the Study of Diabetes (EASD) suggests targeting residual risk in patients with elevated TG (> 2.2 mmol/L), with dietary and lifestyle advice and improved glucose control[[33](#_ENREF_33)], post first-line treatment. The Endocrine Society task force agrees with the NCEP ATP III treatment goals and recommends fibrates as first-line treatment for lowering triglycerides in patients at-risk for pancreatitis[[34](#_ENREF_34)].

The International Atherosclerosis Society position paper recognises the atherogenecity of VLDL and triglycerides and also favours non-HDL cholesterol as the main target for therapy, optimally at < 3.40 mmol/L[[35](#_ENREF_35)]. The American College of Cardiology (ACC)/AHA published a new clinical practice guideline for the treatment of elevated blood cholesterol in people at high risk for CVD. The guidelines do not provide recommendations for specific LDL-cholesterol or non-HDL targets and instead defines four major groups of primary and secondary prevention patients for whom LDL lowering is proven to be most beneficial[[36](#_ENREF_36)]. Future guidelines to cover the treatment of HTG are proposed. A recent review by Hegele *et al*[[37](#_ENREF_37)] recommended the simplification and redefinition of HTG: < 2.0 mmol/L as normal, 2.0-10.0 mmol/L as mild-to-moderate and > 10.0 mmol/L as severe; with desirable targets of < 1.7 mmol/L for triglycerides, < 2.6 mmol/L for non-HDL cholesterol and < 0.8 g/L for apoB in high-risk patients

Treatment of HTG depends on its severity, co-existing lipid abnormalities and overall cardiovascular risk. Severe HTG serves as increased risk of pancreatitis and warrants treatment to acutely reduce triglyceride levels. Current therapeutic strategies include diet and lifestyle modification, pharmacotherapy and in rare cases, continuous insulin infusion and apheresis.

***Dietary and lifestyle modifications***

Lifestyle interventions are central for controlling hyperglycaemia and HTG in patients with type 2 diabetic patients and impaired fasting glucose. These interventions include weight reduction, altered dietary composition, exercise and regulation of alcohol consumption. In type 2 diabetes, modest (5%-10%) weight loss can lower plasma triglyceride levels by up to 25%[[38](#_ENREF_38),[39](#_ENREF_39)] and normalise postprandial triglyceride concentration[[40](#_ENREF_40)]. Physical activity can aid the maintenance of weight loss achieved through caloric restrictions[[41](#_ENREF_41)], although evidence for linking lifestyle modifications and sustained weight is limited[[42](#_ENREF_42)].

The recently published Look AHEAD trial, an intensive lifestyle intervention in type 2 diabetics, employing weight loss through caloric restriction and increased physical activity did not reduce the rate of cardiovascular events[[43](#_ENREF_43)]. Whether alterations in dietary composition, such as with the Mediterranean diet, improves clinical outcome in diabetes warrants additional investigation[[44](#_ENREF_44)], though the Mediterranean and low-carbohydrate diet can produce a greater reduction in triglyceride levels compared to the restricted-calorie diet in moderately in obese individuals[[45](#_ENREF_45),[46](#_ENREF_46)]. Plant sterols have been suggested for lowering TG in individuals with overt HTG[[47](#_ENREF_47)]. Alcohol abstinence in patients with excessive alcohol intake can markedly lower plasma triglyceride levels[[48](#_ENREF_48),[49](#_ENREF_49)]. Smoking cessation is also imperative[[50](#_ENREF_50)].

***Pharmacotherapy***

**Statin monotherapy:** Statin therapy is the cornerstone of treatment of dyslipidaemia in diabetes. Whilst reaching the LDL cholesterol target in most patients, only modest effects are exerted on triglyceride and HDL cholesterol. Hence, diabetics with HTG often have residual CVD risk[[51](#_ENREF_51)] in spite of an optimal LDL cholesterol target. Statins may lower plasma triglyceride by increasing lipolysis and the clearance of TRLs, particularly with potent statins such as atorvastatin and rosuvastatin (up to 26% and 28% reduction in plasma triglyceride, respectively)[[52-54](#_ENREF_52)]. Large statin outcome trials have supported its use in reducing coronary events and mortality[[55-58](#_ENREF_55)]. All trials to-date have not specifically selected for HTG and in diabetics. However, sub-group analyses have been undertaken showing risk prevention with pravastatin[[59](#_ENREF_59)], simvastatin[[60](#_ENREF_60)] and rosuvastatin[[61](#_ENREF_61)] in a subset of patients with high plasma triglyceride, recently reviewed by Maki *et al*[[62](#_ENREF_62)], and supporting statins as first line of therapy.Whilst use of higher doses of statin has been linked to incidence of diabetes[[63-65](#_ENREF_63)], the benefits of statin therapy for reducing CVD risk and events are outweighed for all diabetic patients with high CVD risk[57,[63](#_ENREF_63)]. Aminotransferase, creatine kinase, creatinine and glucose should be monitored prior to initiating statins and before initiating a second agent, if required.

**Fibrates and statin-fibrate combination:** Fibrates (gemfibrozil, fenofibrate) act on peroxisome proliferator-activated receptor alpha (PPAR-alpha). Fibrates decreases hepatic VLDL secretion and can confer an up to 30% reduction in plasma triglyceride, TRL remnants and apoB[[66](#_ENREF_67)]. Five fibrate trials have undertaken secondary analyses in high triglyceride subgroups[[67-79](#_ENREF_68)], two of these trials were in type 2 diabetic patients[[70-72](#_ENREF_71)] and one had a subset of diabetics[[73](#_ENREF_74),[74](#_ENREF_75)]. Collectively, these trials advocate the use of fibrates in reducing CVD events among patients with a high triglyceride and low HDL cholesterol levels[[75-78](#_ENREF_76)]. Of note, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study showed that fenofibrate decreased progression of diabetic retinopathy[[79](#_ENREF_80)],though unrelated to dyslipidaemia, and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study also showed a delay in the onset of eye complications[[80](#_ENREF_81)].Meta-analyses suggest that fibrates are useful for treatment of HTG[[76](#_ENREF_77)] in diabetic patients[[71](#_ENREF_72),[81](#_ENREF_82),[82](#_ENREF_83)]. Every 0.10 mmol/L reduction in triglyceride with fibrates confers a 5% reduction in CVD event, although no benefits were found on cardiovascular mortality[[77](#_ENREF_78),[78](#_ENREF_79)].

**Niacin and statin-niacin combination:** Niacin can decrease plasma triglyceride by 30%[[83](#_ENREF_84)] via the inhibition of hepatic diacylglycerol acyltransferase-2 (DGAT-2), a rate-limiting enzyme of triglyceride synthesis. Despite the earlier studies showing reduced mortality[[84](#_ENREF_85)] and regression of subclinical atherosclerosis[[85-87](#_ENREF_86)], the current use of niacin has been challenged by two large recent clinical trials which have failed to show significant benefits on CVD events[[88](#_ENREF_89),[89](#_ENREF_90)] in spite of positive changes in lipid parameters. Both trials have limitations. The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health) study was underpowered and confounded by the higher statin and/or ezetimibe doses to match LDL cholesterol between groups[[88](#_ENREF_89)]. The HPS2-THRIVE (Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events) is the largest extend-release niacin trial to-date combined with laropiprant, a prostaglandin D2 inhibitor[[89](#_ENREF_90)]. Despite no significant benefit on primary CVD endpoints, a recent sub-analysis in patients with both high triglyceride (> 2.24 mmol/L) and low HDL cholesterol (< 0.85 mmol/L) showed a trend towards benefit with niacin, although not reaching statistical significance (HR = 0.74, *P* = 0.073)[[90](#_ENREF_91)]. Of note, the lack of potential benefit or harm in the HPS2-THRIVE study may not necessarily be due to niacin, but potentially to laropiprant.The safety of niacin use in type 2 diabetes has previously been questioned owing to impairment in glycaemic control and insulin sensitivity[[91-93](#_ENREF_92)]. However, two prospective trials have showed that the effect of niacin on glycaemic control is minimal in a majority of patients with stable diabetes[[94](#_ENREF_95)] and with no changes in low-dose (1 g/d) niacin[[95](#_ENREF_96)].

**Ezetimibe and statin-ezetimibe combination:** Ezetimibe inhibits intestinal cholesterol absorption and primarily lowers LDL cholesterol via the Niemann-Pick C1-Like 1 protein. Ezetimibe has minimal effects in lowering plasma fasting triglyceride (8%)[[96](#_ENREF_97)]. A more prominent effect is observed in ameliorating postprandial lipaemia and lowering TRL remnants in spite of background statin[[97](#_ENREF_98),[98](#_ENREF_99)].In a 6-wk trial of simvastatin–ezetimibe vs. simvastatin monotherapy, fasting and postprandial plasma triglyceride and apoB-48 concentrations were lowered in type 2 diabetic patients[[99](#_ENREF_100)]. However, intensive lipid lowering with a statin plus ezetimibe may not consistently lower subclinical carotid atherosclerosis in type 2 diabetes, although progression of carotid artery intima-media thickness was inhibited with the combination[[100](#_ENREF_101),[101](#_ENREF_102)]. The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) study that is currently entering completion will endeavour to provide definitive evidence for the role of ezetimibe in high risk subjects on optimal statin therapy[[102](#_ENREF_103),[103](#_ENREF_104)].

**n-3 fatty acid and statin-n-3 fatty acid combination:** Supplemental n-3 polyunsaturated fatty acids (PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are well known to improve HTG[[104](#_ENREF_105)]. However, recent clinical outcome trials with have failed to show significant CVD benefits in high risk subjects including diabetics[[105](#_ENREF_106),[106](#_ENREF_107)]. Both trials were undertaken against a background of optimal therapy, including statins. Also, patients were not selected for elevated plasma triglyceride levels. Pure EPA (1800 mg/d), added to statin therapy, showed promise in the Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS) with major coronary events reduced by 19% (*P* = 0.011) in hypercholesterolaemic patients[[107](#_ENREF_108)]. Two 12-wk EPA (AMR101) intervention trials in patients with very high[[108](#_ENREF_109)] and persistent[[10](#_ENREF_110)9] baseline triglyceride observed significant reductions in triglyceride levels. The greatest decrease was seen in the highest triglyceride tertile where there was a 31% reduction compared to placebo on 4 g/d of AMR101. The Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) is in progress and will endeavour obtain the CVD outcome data with AMR101 4 g/d in high-risk patients with HTG and at-target LDL cholesterol on statin therapy[[110](#_ENREF_111)].There are also recent data suggesting an increased risk of prostate cancer with high dietary intake of n-3 PUFAs[[111](#_ENREF_112)]. Hence, caution is warranted when recommending long-term intake.

**Incretin-based therapy:** Incretins, such as glucagon-like peptide-1 (GLP-1), are insulinotropic, gut-derived hormones secreted in response to diet. GLP-1 receptor analogs such as liraglutide and exenatide, delay gastric emptying and this parallels the reduction in postprandial triglyceride response[[112](#_ENREF_113)]. This mechanism may ameliorate impaired TRL metabolism in type 2 diabetes. By increasing plasma concentrations of GLP-1, Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin, saxagliptin and alogliptin, can improve insulin sensitivity, β-cell function[[113](#_ENREF_114)] and postprandial glycaemia[[114](#_ENREF_115)] and lipaemia[[115](#_ENREF_116)]. These agents could potentially prevent CVD events, independent of changes in glucose and lipid metabolism. A recent saxagliptin outcome trial failed to demonstrate significant changes in ischaemic events, though the rate of heart failure increased significantly[[116](#_ENREF_117)]. Similarly, a trial in type 2 diabetic patients post-acute coronary syndrome with aloglipitin did not improve cardiovascular event rates compared with placebo[[117](#_ENREF_118)]. Further investigation is required to clarify their mechanism and use in type 2 diabetes.

**MANAGEMENT OF SEVERE HYPERTRIGLYCERIDAEMIA IN TYPE 2 DIABETES**

***Insulin infusion, apheresis and gene replacement therapy***

In severe cases of diabetic HTG and poorly controlled diabetes, continuous intravenous insulin infusion appears to be beneficial in restoring serum glucose and triglyceride[[118](#_ENREF_119)]. Most of these patients will have an underlying genetic defect in TRL metabolism. A recent study in a group of 15 diabetics with a median triglyceride concentration of 26.23 mmol/L at admission had their triglyceride levels corrected to a median of 5.75 mmol/L at discharge with an average of 48 hours of continuous insulin infusion[[119](#_ENREF_120)]. For prevention of recurrent severe HTG in susceptible patients, counselling on medication adherence and long-term diet and lifestyle medications should be considered[[120](#_ENREF_121)].

In extremely severe HTG and drug refractory HTG, plasma apheresis may be required[[121](#_ENREF_122),[122](#_ENREF_123)], particularly with severe chylomicronaemia complicated by acute pancreatitis. A single session of apheresis can dramatically lower excessive triglyceride levels, 65.8% reduction in 2 h[[123](#_ENREF_124),[124](#_ENREF_125)]. This method of triglyceride lowering is only indicated in medical emergencies owing to high costs and limited availability[[125](#_ENREF_126)]. Further study is required to clarify the role of plasma exchange in the treatment of hyperlipidaemic pancreatitis.

In patients genetically diagnosed with familial LPL deficiency, Glybera® (alipogene tiparvovec; Amsterdam Molecular Therapeutics, Amsterdam, the Netherlands) is the first approved gene-replacement therapy[[126](#_ENREF_127),[127](#_ENREF_128)]. Glybera® has only been studied in 27 patients, in whom the agent was well tolerated and with plasma triglyceride concentration significantly lowered with reduced rates of acute pancreatitis[[126](#_ENREF_127)]. Long-term follow-up data and cost-effectiveness studies is warranted[[126](#_ENREF_127),[127](#_ENREF_128)].

**CONCLUSION**

HTG is common in type 2 diabetes. HTG associates with a spectrum of cardiometabolic risk factors and increases CVD risk in type 2 diabetes. Dietary and lifestyle modification involving weight loss and exercise is fundamental to the management of HTG. Improved glyacaemic control with use of metformin, DPP-4 inhibitors and insulin can also improve HTG. The expression of HTG in context of diabetes may depend on co-existing monogenic and/or multigenic disorders of lipid metabolism, such as familial combined hyperlipidaemia, familial hypertriglyceridaemia and type II hyperlipoproteinaemia. Statins are the first-line of lipid-lowering therapy to target LDL cholesterol and triglycerides. Current evidence supports the use of fenofibrate in type 2 diabetics, with high triglyceride and low HDL, but also to prevent and treat diabetic retinopathy. More evidence is required from CVD outcome trials for the other add-on options, some of which are currently underway. Several new therapies with potential applications for treating HTG are DGAT inhibitors, microsomal triglyceride transfer protein inhibitors, and apoC-III antisense oligonucleotides. These will agents will require to be tested for efficacy, safety and cost-effectiveness in future clinical trials.

**REFERENCES**

1 **Murad MH**, Hazem A, Coto-Yglesias F, Dzyubak S, Gupta S, Bancos I, Lane MA, Erwin PJ, Berglund L, Elraiyah T, Montori VM. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. *BMC Endocr Disord* 2012; **12**: 2 [PMID: 22463676 DOI: 10.1186/1472-6823-12-2]

2 **Leiter LA**, Lundman P, da Silva PM, Drexel H, Jünger C, Gitt AK. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. *Diabet Med* 2011; **28**: 1343-1351 [PMID: 21679231 DOI: 10.1111/j.1464-5491.2011.03360.x]

3 **Feher M**, Greener M, Munro N. Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus. *Diabetes Metab Syndr Obes* 2013; **6**: 11-15 [PMID: 23341741 DOI: 10.2147/DMSO.S35053]

4 **Johansen CT**, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. *J Lipid Res* 2011; **52**: 189-206 [PMID: 21041806 DOI: 10.1194/jlr.R009720]

5 **Surendran RP**, Visser ME, Heemelaar S, Wang J, Peter J, Defesche JC, Kuivenhoven JA, Hosseini M, Péterfy M, Kastelein JJ, Johansen CT, Hegele RA, Stroes ES, Dallinga-Thie GM. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. *J Intern Med* 2012; **272**: 185-196 [PMID: 22239554 DOI: 10.1111/j.1365-2796.2012.02516.x]

6 **Simental-Mendía LE**, Rodríguez-Morán M, Simental-Saucedo L, Guerrero-Romero F. Insulin secretion is increased in non-diabetic subjects with fasting hypertriglyceridaemia. *Diabetes Metab Res Rev* 2013; **29**: 214-219 [PMID: 23225554 DOI: 10.1002/dmrr.2379]

7 **Ooi EM**, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. *Clin Sci (Lond)* 2008; **114**: 611-624 [PMID: 18399797 DOI: 10.1042/CS20070308]

8 **Caron S**, Verrijken A, Mertens I, Samanez CH, Mautino G, Haas JT, Duran-Sandoval D, Prawitt J, Francque S, Vallez E, Muhr-Tailleux A, Berard I, Kuipers F, Kuivenhoven JA, Biddinger SB, Taskinen MR, Van Gaal L, Staels B. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. *Arterioscler Thromb Vasc Biol* 2011; **31**: 513-519 [PMID: 21183731 DOI: 10.1161/ATVBAHA.110.220723]

9 **Chait A**, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. *Am J Med* 1993; **94**: 350-356 [PMID: 8475928 DOI: 10.1016/0002-9343(93)90144-E]

10 **Durlach V**, Attia N, Zahouani A, Leutenegger M, Girard-Globa A. Postprandial cholesteryl ester transfer and high density lipoprotein composition in normotriglyceridemic non-insulin-dependent diabetic patients. *Atherosclerosis* 1996; **120**: 155-165 [PMID: 8645357 DOI: 10.1016/0021-9150(95)05697-1]

11 **Lamarche B**, Rashid S, Lewis GF. HDL metabolism in hypertriglyceridemic states: an overview. *Clin Chim Acta* 1999; **286**: 145-161 [PMID: 10511289 DOI: 10.1016/S0009-8981(99)00098-4]

12 **Durrington PN**. Triglycerides are more important in atherosclerosis than epidemiology has suggested. *Atherosclerosis* 1998; **141 Suppl 1**: S57-S62 [PMID: 9888644 DOI: 10.1016/S0021-9150(98)00219-6]

13 **Johansen CT**, Hegele RA. Using Mendelian randomization to determine causative factors in cardiovascular disease. *J Intern Med* 2013; **273**: 44-47 [PMID: 22928522 DOI: 10.1111/j.1365-2796.2012.02586.x]

14 **Friedewald WT**, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; **18**: 499-502 [PMID: 4337382]

15 **Chan DC**, Pang J, Romic G, Watts GF. Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. *Curr Atheroscler Rep* 2013; **15**: 309 [PMID: 23345190 DOI: 10.1007/s11883-013-0309-9]

16 **Ganda OP**, Jumes CG, Abrahamson MJ, Molla M. Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia. *Diabetes Res Clin Pract* 2012; **97**: 51-56 [PMID: 22459987 DOI: 10.1016/j.diabres.2012.02.013]

17 **Boekholdt SM**, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Ridker PM, Kastelein JJ. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. *JAMA* 2012; **307**: 1302-1309 [PMID: 22453571 DOI: 10.1001/jama.2012.366]

18 **Lemieux I**, Poirier P, Bergeron J, Alméras N, Lamarche B, Cantin B, Dagenais GR, Després JP. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? *Can J Cardiol* 2007; **23 Suppl B**: 23B-31B [PMID: 17932584 DOI: 10.1016/S0828-282X(07)71007-3]

19 **He S**, Zheng Y, Shu Y, He J, Wang Y, Chen X. Hypertriglyceridemic waist might be an alternative to metabolic syndrome for predicting future diabetes mellitus. *PLoS One* 2013; **8**: e73292 [PMID: 24039903 DOI: 10.1371/journal.pone.0073292]

20 **Sam S**, Haffner S, Davidson MH, D'Agostino RB, Feinstein S, Kondos G, Perez A, Mazzone T. Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. *Diabetes Care* 2009; **32**: 1916-1920 [PMID: 19592623 DOI: 10.2337/dc09-0412]

21 **de Graaf FR**, Schuijf JD, Scholte AJ, Djaberi R, van Velzen JE, Roos CJ, Kroft LJ, de Roos A, van der Wall EE, Wouter Jukema J, Després JP, Bax JJ. Usefulness of hypertriglyceridemic waist phenotype in type 2 diabetes mellitus to predict the presence of coronary artery disease as assessed by computed tomographic coronary angiography. *Am J Cardiol* 2010; **106**: 1747-1753 [PMID: 21126619 DOI: 10.1016/j.amjcard.2010.08.015]

22 **Amini M**, Esmaillzadeh A, Sadeghi M, Mehvarifar N, Amini M, Zare M. The association of hypertriglyceridemic waist phenotype with type 2 diabetes mellitus among individuals with first relative history of diabetes. *J Res Med Sci* 2011; **16**: 156-164 [PMID: 22091225]

23 **Carlsson AC**, Risérus U, Arnlöv J. Hypertriglyceridemic waist phenotype is associated with decreased insulin sensitivity and incident diabetes in elderly men. *Obesity (Silver Spring)* 2014; **22**: 526-529 [PMID: 23512911 DOI: 10.1002/oby.20434]

24 **Blackburn P**, Lemieux I, Lamarche B, Bergeron J, Perron P, Tremblay G, Gaudet D, Després JP. Hypertriglyceridemic waist: a simple clinical phenotype associated with coronary artery disease in women. *Metabolism* 2012; **61**: 56-64 [PMID: 21733531 DOI: 10.1016/j.metabol.2011.05.017]

25 **Arsenault BJ**, Lemieux I, Després JP, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SM. The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study. *CMAJ* 2010; **182**: 1427-1432 [PMID: 20643837 DOI: 10.1503/cmaj.091276]

26 **St-Pierre J**, Lemieux I, Perron P, Brisson D, Santuré M, Vohl MC, Després JP, Gaudet D. Relation of the "hypertriglyceridemic waist" phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus. *Am J Cardiol* 2007; **99**: 369-373 [PMID: 17261400 DOI: 10.1016/j.amjcard.2006.08.041]

27 **Chapman MJ**, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *Eur Heart J* 2011; **32**: 1345-1361 [PMID: 21531743 DOI: 10.1093/eurheartj/ehr112]

28 **Miller M**, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation* 2011; **123**: 2292-2333 [PMID: 21502576 DOI: 10.1161/CIR.0b013e3182160726]

29 **Reiner Z**, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 2011; **32**: 1769-1818 [PMID: 21712404 DOI: 10.1093/eurheartj/ehr158]

30 **American Diabetes Association**. Standards of medical care in diabetes--2012. *Diabetes Care* 2012; **35 Suppl 1**: S11-S63 [PMID: 22187469 DOI: 10.2337/dc12-s011]

31 National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Available from http: //www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf

32 **Brunzell JD**, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. *Diabetes Care* 2008; **31**: 811-822 [PMID: 18375431 DOI: 10.2337/dc08-9018]

33 **Rydén L**, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2013; **34**: 3035-3087 [PMID: 23996285 DOI: 10.1093/eurheartj/eht108]

34 **Berglund L**, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2012; **97**: 2969-2989 [PMID: 22962670 DOI: 10.1210/jc.2011-3213]

35 **Grundy SM**. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. *J Clin Lipidol* 2013; **7**: 561-565 [PMID: 24314355 DOI: 10.1016/j.jacl.2013.10.001]

36 **Stone NJ**, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013; [Epub ahead of print] [PMID: 24222016 DOI: 10.1161/01.cir.0000437738.63853.7a]

37 **Hegele RA**, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Borén J, Bruckert E, Catapano AL, Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AFH, Stroes E, Taskinen M-R, Tybjærg-Hansen A, Watts GF, Wiklund O: The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. *Lancet Diabetes Endocrinol* 2013; [Epub ahead of print] [DOI: [10.1016/S2213-8587(13)70191-8](http://dx.doi.org/10.1016/S2213-8587(13)70191-8)]

38 **Wing RR**, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes Care* 2011; **34**: 1481-1486 [PMID: 21593294 DOI: 10.2337/dc10-2415]

39 **Dattilo AM**, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr* 1992; **56**: 320-328 [PMID: 1386186]

40 **Maraki MI**, Aggelopoulou N, Christodoulou N, Anastasiou CA, Toutouza M, Panagiotakos DB, Kavouras SA, Magkos F, Sidossis LS. Lifestyle intervention leading to moderate weight loss normalizes postprandial triacylglycerolemia despite persisting obesity. *Obesity (Silver Spring)* 2011; **19**: 968-976 [PMID: 20885389 DOI: 10.1038/oby.2010.218]

41 **Mooradian AD**. Obesity: a rational target for managing diabetes mellitus. *Growth Horm IGF Res* 2001; **11 Suppl A**: S79-S83 [PMID: 11527093 DOI: 10.1016/S1096-6374(01)80013-7]

42 **Aucott L**, Gray D, Rothnie H, Thapa M, Waweru C. Effects of lifestyle interventions and long-term weight loss on lipid outcomes - a systematic review. *Obes Rev* 2011; **12**: e412-e425 [PMID: 21371252 DOI: 10.1111/j.1467-789X.2010.00819.x]

43 **Wing RR**, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med* 2013; **369**: 145-154 [PMID: 23796131 DOI: 10.1056/NEJMoa1212914]

44 **Estruch R**, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* 2013; **368**: 1279-1290 [PMID: 23432189 DOI: 10.1056/NEJMoa1200303]

45 **Schwarzfuchs D**, Golan R, Shai I. Four-year follow-up after two-year dietary interventions. *N Engl J Med* 2012; **367**: 1373-1374 [PMID: 23034044 DOI: 10.1056/NEJMc1204792]

46 **Nordmann AJ**, Suter-Zimmermann K, Bucher HC, Shai I, Tuttle KR, Estruch R, Briel M. Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. *Am J Med* 2011; **124**: 841-51.e2 [PMID: 21854893 DOI: 10.1016/j.amjmed.2011.04.024]

47 **Theuwissen E**, Plat J, van der Kallen CJ, van Greevenbroek MM, Mensink RP. Plant stanol supplementation decreases serum triacylglycerols in subjects with overt hypertriglyceridemia. *Lipids* 2009; **44**: 1131-1140 [PMID: 19904567 DOI: 10.1007/s11745-009-3367-6]

48 **Brinton EA**. Effects of ethanol intake on lipoproteins. *Curr Atheroscler Rep* 2012; **14**: 108-114 [PMID: 22350634 DOI: 10.1007/s11883-012-0230-7]

49 **Bessembinders K**, Wielders J, van de Wiel A. Severe hypertriglyceridemia influenced by alcohol (SHIBA). *Alcohol Alcohol* 2011; **46**: 113-116 [PMID: 21245063 DOI: 10.1093/alcalc/agq088]

50 **Kabagambe EK**, Ordovas JM, Tsai MY, Borecki IB, Hopkins PN, Glasser SP, Arnett DK. Smoking, inflammatory patterns and postprandial hypertriglyceridemia. *Atherosclerosis* 2009; **203**: 633-639 [PMID: 18804210 DOI: 10.1016/j.atherosclerosis.2008.08.005]

51 **Hamilton SJ**, Watts GF. Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. *Rev Diabet Stud* 2013; **10**: 191-203 [PMID: 24380092 DOI: 10.1002/pdi.1610]

52 **Ginsberg HN**. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. *J Clin Endocrinol Metab* 2006; **91**: 383-392 [PMID: 16291700 DOI: 10.1210/jc.2005-2084]

53 **Deedwania PC**, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. *Am J Cardiol* 2005; **95**: 360-366 [PMID: 15670545 DOI: 10.1016/j.amjcard.2004.09.034]

54 **Jones PH**, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR\* Trial). *Am J Cardiol* 2003; **92**: 152-160 [PMID: 12860216 DOI: 10.1016/S0002-9149(03)00530-7]

55 **Pedersen TR**, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyörälä K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. *Atheroscler Suppl* 2004; **5**: 81-87 [PMID: 15531279 DOI: 10.1016/S0140-6736(94)90566-5]

56 **Ridker PM**, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. *Lancet* 2012; **380**: 565-571 [PMID: 22883507 DOI: 10.1016/S0140-6736(12)61190-8]

57 **Kearney PM**, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008; **371**: 117-125 [PMID: 18191683 DOI: 10.1016/S0140-6736(08)60104-X]

58 **Shepherd J**, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. *Clin J Am Soc Nephrol* 2007; **2**: 1131-1139 [PMID: 17942759 DOI: 10.2215/CJN.04371206]

59 **Shepherd J**, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995; **333**: 1301-1307 [PMID: 7566020 DOI: 10.1056/NEJM199511163332001]

60 **Ballantyne CM**, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. *Circulation* 2001; **104**: 3046-3051 [PMID: 11748098 DOI: 10.1161/hc5001.100624]

61 **Glynn RJ**, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. *Ann Intern Med* 2010; **152**: 488-96, W174 [PMID: 20404379 DOI: 10.7326/0003-4819-152-8-201004200-00005]

62 **Maki KC**, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. *J Clin Lipidol* 2012; **6**: 413-426 [PMID: 23009777 DOI: 10.1016/j.jacl.2012.04.003]

63 **Sattar N**, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* 2010; **375**: 735-742 [PMID: 20167359 DOI: 10.1016/S0140-6736(09)61965-6]

64 **Culver AL**, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. *Arch Intern Med* 2012; **172**: 144-152 [PMID: 22231607 DOI: 10.1001/archinternmed.2011.625]

65 **Preiss D**, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. *JAMA* 2011; **305**: 2556-2564 [PMID: 21693744 DOI: 10.1001/jama.2011.860]

66 **Staels B**. Fibrates in CVD: a step towards personalised medicine. *Lancet* 2010; **375**: 1847-1848 [PMID: 20510999 DOI: 10.1016/S0140-6736(10)60758-1]

67 **Frick MH**, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. *N Engl J Med* 1987; **317**: 1237-1245 [PMID: 3313041 DOI: 10.1056/NEJM198711123172001]

68 **Manninen V**, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. *Circulation* 1992; **85**: 37-45 [PMID: 1728471 DOI: 10.1161/01.CIR.85.1.37]

69 **Schlesinger Z**, Vered Z, Friedenson A, Reisin L, Jafari J, Flieb T, Sclarovsky S, Friedman Y, Ostfeld B, Solodky A. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. *Circulation* 2000; **102**: 21-27 [PMID: 10880410 DOI: 10.1161/01.CIR.102.1.21]

70 **Keech A**, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet* 2005; **366**: 1849-1861 [PMID: 16310551 DOI: 10.1016/S0140-6736(05)67667-2]

71 **Scott R**, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetes Care* 2009; **32**: 493-498 [PMID: 18984774 DOI: 10.2337/dc08-1543]

72 **Ginsberg HN**, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med* 2010; **362**: 1563-1574 [PMID: 20228404 DOI: 10.1056/NEJMoa1001282]

73 **Bloomfield Rubins H**, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). *Circulation* 2001; **103**: 2828-2833 [PMID: 11401940 DOI: 10.1161/01.CIR.103.23.2828]

74 **Rubins HB**, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). *Arch Intern Med* 2002; **162**: 2597-2604 [PMID: 12456232 DOI: 10.1001/archinte.162.22.2597]

75 **Rizos E**, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. *Int J Cardiol* 2002; **82**: 199-207; discussion 207-8 [PMID: 11911905 DOI: 10.1016/S0167-5273(01)00625-8]

76 **Lee M**, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. *Atherosclerosis* 2011; **217**: 492-498 [PMID: 21592479 DOI: 10.1016/j.atherosclerosis.2011.04.020]

77 **Jun M**, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet* 2010; **375**: 1875-1884 [PMID: 20462635 DOI: 10.1016/S0140-6736(10)60656-3]

78 **Bruckert E**, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. *J Cardiovasc Pharmacol* 2011; **57**: 267-272 [PMID: 21052016 DOI: 10.1097/FJC.0b013e318202709f]

79 **Keech AC**, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. *Lancet* 2007; **370**: 1687-1697 [PMID: 17988728 DOI: 10.1016/S0140-6736(07)61607-9]

80 **Ismail-Beigi F**, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* 2010; **376**: 419-430 [PMID: 20594588 DOI: 10.1016/S0140-6736(10)60576-4]

81 **Tonkin AM**, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Circulation* 2010; **122**: 850-852 [PMID: 20733114 DOI: 10.1161/CIRCULATIONAHA.110.960112]

82 **Elam M**, Lovato L, Ginsberg H: The ACCORD-Lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. *Clin Lipidol* 2011; **6**: 9-20 [DOI: 10.2217/clp.10.84]

83 **Chapman MJ**, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. *Pharmacol Ther* 2010; **126**: 314-345 [PMID: 20153365 DOI: 10.1016/j.pharmthera.2010.01.008]

84 **Canner PL**, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. *J Am Coll Cardiol* 1986; **8**: 1245-1255 [PMID: 3782631 DOI: 10.1016/S0735-1097(86)80293-5]

85 **Brown BG**, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 2001; **345**: 1583-1592 [PMID: 11757504 DOI: 10.1056/NEJMoa011090]

86 **Taylor AJ**, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. *Circulation* 2004; **110**: 3512-3517 [PMID: 15537681 DOI: 10.1161/01.CIR.0000148955.19792.8D]

87 **Taylor AJ**, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. *Curr Med Res Opin* 2006; **22**: 2243-2250 [PMID: 17076985 DOI: 10.1185/030079906X148508]

88 **Boden WE**, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med* 2011; **365**: 2255-2267 [PMID: 22085343 DOI: 10.1056/NEJMoa1107579]

89 **Haynes R**, Jiang L, Hopewell JC, Li J, Chen F, Parish S, Landray MJ, Collins R, Armitage J, Collins R. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. *Eur Heart J* 2013; **34**: 1279-1291 [PMID: 23444397 DOI: 10.1093/eurheartj/eht055]

90 **Guyton JR**, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). *J Am Coll Cardiol* 2013; **62**: 1580-1584 [PMID: 23916935 DOI: 10.1016/j.jacc.2013.07.023]

91 **Garg A**. Lipid-lowering therapy and macrovascular disease in diabetes mellitus. *Diabetes* 1992; **41 Suppl 2**: 111-115 [PMID: 1526329 DOI: 10.2337/diab.41.2.S111]

92 **Poynten AM**, Gan SK, Kriketos AD, O'Sullivan A, Kelly JJ, Ellis BA, Chisholm DJ, Campbell LV. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. *Metabolism* 2003; **52**: 699-704 [PMID: 12800094 DOI: 10.1016/S0026-0495(03)00030-1]

93 **Alvarsson M**, Grill V. Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. *Scand J Clin Lab Invest* 1996; **56**: 563-570 [PMID: 8903118 DOI: 10.3109/00365519609088812]

94 **Elam MB**, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. *JAMA* 2000; **284**: 1263-1270 [PMID: 10979113 DOI: 10.1001/jama.284.10.1263]

95 **Grundy SM**, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. *Arch Intern Med* 2002; **162**: 1568-1576 [PMID: 12123399 DOI: 10.1001/archinte.162.14.1568]

96 **Pandor A**, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN, Chilcott J. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. *J Intern Med* 2009; **265**: 568-580 [PMID: 19141093 DOI: 10.1111/j.1365-2796.2008.02062.x]

97 **Kikuchi K**, Nezu U, Inazumi K, Miyazaki T, Ono K, Orime K, Shirakawa J, Sato K, Koike H, Wakasugi T, Sato M, Kawakami C, Watanabe S, Yamakawa T, Terauchi Y. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. *J Atheroscler Thromb* 2012; **19**: 1093-1101 [PMID: 22878697 DOI: 10.5551/jat.12427]

98 **Nakamura T**, Hirano M, Kitta Y, Fujioka D, Saito Y, Kawabata K, Obata JE, Watanabe Y, Watanabe K, Kugiyama K. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. *J Cardiol* 2012; **60**: 12-17 [PMID: 22445441 DOI: 10.1016/j.jjcc.2012.02.005]

99 **Bozzetto L**, Annuzzi G, Corte GD, Patti L, Cipriano P, Mangione A, Riccardi G, Rivellese AA. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. *Atherosclerosis* 2011; **217**: 142-148 [PMID: 21481394 DOI: 10.1016/j.atherosclerosis.2011.03.012]

100 **Fleg JL**, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, Silverman A, Galloway JM, Henderson JA, Weir MR, Wilson C, Stylianou M, Howard WJ. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. *J Am Coll Cardiol* 2008; **52**: 2198-2205 [PMID: 19095139 DOI: 10.1016/j.jacc.2008.10.031]

101 **Taylor AJ**, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. *N Engl J Med* 2009; **361**: 2113-2122 [PMID: 19915217 DOI: 10.1056/NEJMoa0907569]

102 **Cannon CP**, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. *Am Heart J* 2008; **156**: 826-832 [PMID: 19061694 DOI: 10.1016/j.ahj.2008.07.023]

103 **Califf RM**, Lokhnygina Y, Cannon CP, Stepanavage ME, McCabe CH, Musliner TA, Pasternak RC, Blazing MA, Giugliano RP, Harrington RA, Braunwald E. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. *Am Heart J* 2010; **159**: 705-709 [PMID: 20435175 DOI: 10.1016/j.ahj.2010.03.004]

104 **Saravanan P**, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. *Lancet* 2010; **376**: 540-550 [PMID: 20638121 DOI: 10.1016/S0140-6736(10)60445-X]

105 **Bosch J**, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *N Engl J Med* 2012; **367**: 309-318 [PMID: 22686415 DOI: 10.1056/NEJMoa1203859]

106 **Roncaglioni MC**, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, Marzona I, Milani V, Silletta MG, Tognoni G, Marchioli R. n-3 fatty acids in patients with multiple cardiovascular risk factors. *N Engl J Med* 2013; **368**: 1800-1808 [PMID: 23656645 DOI: 10.1056/NEJMoa1205409]

107 **Yokoyama M**, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet* 2007; **369**: 1090-1098 [PMID: 17398308 DOI: 10.1016/S0140-6736(07)60527-3]

108 **Bays HE**, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). *Am J Cardiol* 2011; **108**: 682-690 [PMID: 21683321 DOI: 10.1016/j.amjcard.2011.04.015]

109 **Ballantyne CM**, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). *Am J Cardiol* 2012; **110**: 984-992 [PMID: 22819432 DOI: 10.1016/j.amjcard.2012.05.031]

110 **Lairon D**, Defoort C. Effects of nutrients on postprandial lipemia. *Curr Vasc Pharmacol* 2011; **9**: 309-312 [PMID: 21314626 DOI: 10.2174/157016111795495576]

111 **Brasky TM**, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. *J Natl Cancer Inst* 2013; **105**: 1132-1141 [PMID: 23843441 DOI: 10.1093/jnci/djt174]

112 **Meier JJ**, Gethmann A, Götze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. *Diabetologia* 2006; **49**: 452-458 [PMID: 16447057 DOI: 10.1007/s00125-005-0126-y]

113 **Tremblay AJ**, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. *Diabetes Obes Metab* 2011; **13**: 366-373 [PMID: 21226820 DOI: 10.1111/j.1463-1326.2011.01362.x]

114 **Barnett AH**, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. *Curr Med Res Opin* 2012; **28**: 513-523 [PMID: 22313154 DOI: 10.1185/03007995.2012.665046]

115 **Anagnostis P**, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, Mikhailidis DP. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. *Diabetes Obes Metab* 2011; **13**: 302-312 [PMID: 21205117 DOI: 10.1111/j.1463-1326.2010.01345.x]

116 **Scirica BM**, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* 2013; **369**: 1317-1326 [PMID: 23992601 DOI: 10.1056/NEJMoa1307684]

117 **White WB**, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med* 2013; **369**: 1327-1335 [PMID: 23992602 DOI: 10.1056/NEJMoa1305889]

118 **Denecker N**, Decochez K. Poorly controlled type 2 diabetes complicated by an episode of severe hypertriglyceridaemia-induced pancreatitis. *BMJ Case Rep* 2013; **2013**: [PMID: 23632173 DOI: 10.1136/bcr-2012-008455]

119 **Henderson SR**, Maitland R, Mustafa OG, Miell J, Crook MA, Kottegoda SR. Severe hypertriglyceridaemia in Type 2 diabetes mellitus: beneficial effect of continuous insulin infusion. *QJM* 2013; **106**: 355-359 [PMID: 23417910 DOI: 10.1093/qjmed/hcs238]

120 **Schaefer EW**, Leung A, Kravarusic J, Stone NJ. Management of severe hypertriglyceridemia in the hospital: a review. *J Hosp Med* 2012; **7**: 431-438 [PMID: 22128096 DOI: 10.1002/jhm.995]

121 **Seda G**, Meyer JM, Amundson DE, Daheshia M. Plasmapheresis in the management of severe hypertriglyceridemia. *Crit Care Nurse* 2013; **33**: 18-23; quiz 24 [PMID: 23908166 DOI: 10.4037/ccn2013346]

122 **Hovland A**, Hardersen R, Mollnes TE, Lappegård KT. Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia. *JOP* 2010; **11**: 467-469 [PMID: 20818118]

123 **Bayraktaroglu T**, Ozkaya M, Kutluturk F, Azezli AD, Orhan Y. Severe hypertriglyceridemia and triglyceride apheresis. *Endocrine* 2009; **20**: Abstr437.

124 **Chen JH**, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. *World J Gastroenterol* 2004; **10**: 2272-2274 [PMID: 15259080]

125 **Ewald N**, Kloer HU. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis. *Clin Res Cardiol Suppl* 2012; **7**: 31-35 [PMID: 22528130 DOI: 10.1007/s11789-012-0042-x]

126 **Gaudet D**, Méthot J, Déry S, Brisson D, Essiembre C, Tremblay G, Tremblay K, de Wal J, Twisk J, van den Bulk N, Sier-Ferreira V, van Deventer S. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. *Gene Ther* 2013; **20**: 361-369 [PMID: 22717743 DOI: 10.1038/gt.2012.43]

127 **Wierzbicki AS**, Viljoen A. Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. *Expert Opin Biol Ther* 2013; **13**: 7-10 [PMID: 23126631 DOI: 10.1517/14712598.2013.738663]

128 Guidelines for the management of absolute cardiovascular disease risk [article online], 2012. Available from http: //strokefoundation.com.au/site/media/AbsoluteCVD\_GL\_webready.pdf

**P-Reviewers:** Cheung BMY, Ramana KV

**S-Editor:** Zhai HH **L-Editor: E-Editor:**

**Table 1 Clinical categorisation of Hypertriglyceridaemia according to guidelines based on fasting triglyceride concentrations**

|  |  |  |  |
| --- | --- | --- | --- |
| Ref. | Year Published | Triglyceride categories | Triglyceride concentration (mmol/L) |
| National Institutes of Health [[31](#_ENREF_31)] | 2001 | Normal  Borderline high  High  Very high | 1.7  1.7-2.3  2.3-5.6  > 5.6 |
| **Rydén** l[[33](#_ENREF_33)] | 2011 | Desirable  Elevated  Very high  Extremely high | <1.7  1.7-5.5  5.5-25.0  > 25.0 |
| **Berglund** [[34](#_ENREF_34)] | 2012 | Normal  Mild  Moderately high  Severely high  Very severely high | < 1.7  1.7-2.3  2.3-11.2  11.2-22.4  > 22.4 |
| Hegele *et al*[[37](#_ENREF_37)] | 2013 | Normal  Mild-to-moderate  Severe | < 2.0  2.0-10.0  > 10.0 |

**Table 2 Clinical guide for the assessment and treatment of HTG in type 2 diabetes.**

|  |  |
| --- | --- |
| **Steps** |  |
| 1 | Obtain fasting lipid profile |
| 2 | Classify LDL-cholesterol concentration (primary target of therapy)  < 2.60 mmol/L – optimal  2.60-3.39 mmol/L – above optimal  3.40-4.14 mmol/L – borderline high  4.15-4.90 mmol/L – high  > 4.90 mmol/L – very high  Establish therapy:  LDL-cholesterol > 2.60 mmol/L – initiate dietary and lifestyle modifications  LDL-cholesterol > 3.40 mmol/L – consider pharmacotherapy simultaneously with dietary and lifestyle modifications |
| 3 | Identify presence of atherosclerotic disease  Clinical coronary heart disease  Symptomatic carotid artery disease  Peripheral artery disease |
| 4 | Assess:  Glycaemic control  Obesity  Dietary intake (*e.g.,* Fructose, simple sugars, caloric intake)  Physical activity  Determine presence of other risk factors:  Smoking  Hypertension  Family history of premature coronary heart disease (*i.e,.* In first-degree relative, male < 55 years, females < 65 years)  Low HDL-cholesterol, < 1.0 mmol/L |
| 5 | Order of treatment considerations:  Improve glycaemia (dietary and lifestyle modifications)  Treat secondary risk factors  Statins  Fibrates  n-3 fatty acids/niacin |
| 6 | Treat elevated triglyceride if triglyceride concentrations are > 2.30 mmol/L after LDL-cholesterol concentration target of < 2.60 mmol/L is reached  target non-HDL cholesterol (< 3.40 mmol/L)  triglyceride > 2.30 mmol/L – intensify LDL-lowering therapy or add fibrate  triglyceride > 5.60 mmol/L – very low-fat diet (< 15% of calories from fat), weight management, physical activity and add fibrate |

Adapted from the NCEP ATP III guidelines[31]. LDL: Low Density Lipoprotein; HDL: High density lipoprotein.

**Table 3 Recommended treatment targets for diabetic dyslipidaemia**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | NCEP ATP III[[31](#_ENREF_31)] | ADA  [[30](#_ENREF_30)] | NVDPA  [[128](#_ENREF_129)] | European Guidelines[[33](#_ENREF_33)] |
| LDL-cholesterol  (mmol/L) | Very high risk | < 1.8 | < 1.8 | < 2.0 | < 1.8 |
| High risk | < 2.6 | < 2.6 | < 2.0 | < 2.5 |
| Triglycerides  (mmol/L) |  |  | < 1.7 | < 2.0 | < 1.7 |
| HDL-cholesterol  (mmol/L) | Male |  | >1.0 | ≥1.0 | >1.0 |
| Female |  | >1.3 | ≥1.0 | >1.2 |
| Non-HDL cholesterol  (mmol/L) | Very high risk | < 2.6 | < 2.6 | < 2.5 | < 2.6 |
| High risk | < 3.4 | < 3.4 | < 2.5 | < 3.3 |
| ApoB (g/L) | Very high risk |  | < 0.8 |  | < 0.8 |
|  | High risk |  | < 0.9 |  | < 1.0 |

NCEP ATP III: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III); ADA: American Diabetes Association; NVDPA: National Vascular Disease Prevention Alliance of Australia; LDL: Low Density Lipoprotein; HDL: High density lipoprotein.